# Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia

> **NCT06007911** · PHASE1 · WITHDRAWN · sponsor: **Medical College of Wisconsin**

## Conditions studied

- Relapsed Adult AML
- Refractory AML

## Interventions

- **DRUG:** Navitoclax Dose Level -1
- **DRUG:** Navitoclax Dose Level 0
- **DRUG:** Navitoclax Dose Level 1
- **DRUG:** Navitoclax Dose Level 2
- **DRUG:** Venetoclax Dose Level -1
- **DRUG:** Venetoclax Dose Levels 0 to 2
- **DRUG:** Cladribine
- **DRUG:** Cytarabine (Cladribine Low Dose Cytarabine Backbone)
- **DRUG:** Cytarabine (CLAG-M Backbone)
- **DRUG:** Mitoxantrone
- **DRUG:** Granulocyte Colony-Stimulating Factor

## Key facts

- **NCT ID:** NCT06007911
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-08-31
- **Primary completion:** 2025-12
- **Final completion:** 2027-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor withdrew support.
- **Last updated:** 2024-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06007911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06007911, "Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06007911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*